deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01652976

Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma (FOLFOX-D)

Phase II Study of 5-Fluorouracil, Oxaliplatin Plus Dasatinib (FOLFOX-D) in First-line Metastatic Pancreatic Adenocarcinoma

Sponsor: Bristol-Myers Squibb

Conditions Pancreatic Cancer Metastatic
Interventions Dasatinib mFOLFOX6
Updated 17 times since 2017 Last updated: Dec 3, 2020 Started: Jul 31, 2012 Primary completion: Feb 28, 2018 Completion: Jul 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Pancreatic Cancer Metastatic and is currently completed. Bristol-Myers Squibb leads this study, which shows 17 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~May 2018 · 10 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Mar 2019 · 6 months · monthly snapshot~Mar 2019 – ~Jul 2019 · 4 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Apr 2020 · 5 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Dec 2022 · 22 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. Feb 2021 — Dec 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 12 earlier versions

  1. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  2. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Mar 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Sep 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE2

  9. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Jul 2017 — May 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  11. Feb 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • University of Florida
Data source: University of Florida

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations